3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
4
Classical hematology
2
Conditions
Anemia
2
Primary Myelofibrosis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Interventions
Epoetin Alfa
27
Darbepoetin alfa
13
Cytarabine
9
Dalteparin
8
Rivaroxaban
7
Daunorubicin
7
apixaban
6
Etoposide
6
Methotrexate
5
Idarubicin
5
Heparin, Low-Molecular-Weight
5
Cyclophosphamide
5
emicizumab
4
Tinzaparin
4
Thioguanine
4
Mitoxantrone
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Enoxaparin
4
pegfilgrastim
3
hetrombopag
3
epoetin beta
3
Saline Solution
3
Radiotherapy
3
Hydrocortisone
3
Erythropoietin
3
Dexamethasone
3
Aspirin
3
Asparaginase
3
telapristone acetate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
luspatercept
×
Classical hematology
×
Clear all
NCT04717414
2025-07-10
INDEPENDENCE
Celgene
Phase 3
Active not recruiting
313 enrolled
NCT02631070
2021-12-17
MEDALIST
Celgene
Phase 3
Completed
229 enrolled
36 charts
1 FDA